Treatment Strategies Based on Histological Targets against Invasive and Resistant Glioblastoma.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2019
2019
Historique:
received:
13
03
2019
accepted:
02
06
2019
entrez:
20
7
2019
pubmed:
20
7
2019
medline:
20
7
2019
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most common and the most malignant primary brain tumor and is characterized by rapid proliferation, invasion into surrounding normal brain tissues, and consequent aberrant vascularization. In these characteristics of GBM, invasive properties are responsible for its recurrence after various therapies. The histomorphological patterns of glioma cell invasion have often been referred to as the "secondary structures of Scherer." The "secondary structures of Scherer" can be classified mainly into four histological types as (i) perineuronal satellitosis, (ii) perivascular satellitosis, (iii) subpial spread, and (iv) invasion along the white matter tracts. In order to develop therapeutic interventions to mitigate glioma cell migration, it is important to understand the biological mechanism underlying the formation of these secondary structures. The main focus of this review is to examine new molecular pathways based on the histopathological evidence of GBM invasion as major prognostic factors for the high recurrence rate for GBMs. The histopathology-based pharmacological and biological targets for treatment strategies may improve the management of invasive and resistant GBMs.
Identifiants
pubmed: 31320900
doi: 10.1155/2019/2964783
pmc: PMC6610731
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
2964783Références
Toxicol Pathol. 2000 Jan-Feb;28(1):193-201
pubmed: 10669007
Neurol Res. 2000 Jul;22(5):527-32
pubmed: 10935229
Neoplasia. 1999 Aug;1(3):208-19
pubmed: 10935475
Hippocampus. 2006;16(3):321-8
pubmed: 16435310
Cancer. 2006 Oct 1;107(7):1597-606
pubmed: 16955507
Curr Opin Cell Biol. 2006 Dec;18(6):704-9
pubmed: 17046226
Nature. 2006 Dec 7;444(7120):756-60
pubmed: 17051156
Clin Transl Oncol. 2008 May;10(5):262-7
pubmed: 18490242
J Neurol. 1991 Apr;238(2):80-2
pubmed: 1856741
Prog Neurobiol. 2009 May;88(1):41-63
pubmed: 19428961
Nat Rev Neurosci. 2009 Nov;10(11):769-79
pubmed: 19773781
Nature. 2010 Nov 11;468(7321):214-22
pubmed: 21068830
J Theor Biol. 2011 Oct 21;287:131-47
pubmed: 21816160
Acta Neuropathol. 2012 Jul;124(1):83-97
pubmed: 22249620
Oncogene. 2012 Dec 13;31(50):5132-43
pubmed: 22310282
Development. 2012 May;139(9):1535-46
pubmed: 22492350
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
pubmed: 23095881
J Neurooncol. 2013 Jan;111(2):123-32
pubmed: 23179497
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
PLoS One. 2013 Aug 15;8(8):e72134
pubmed: 23967279
Acta Neuropathol. 1989;78(3):270-82
pubmed: 2475009
Neuro Oncol. 2014 Dec;16(12):1575-84
pubmed: 25082799
Cancer Immunol Immunother. 2015 Jan;64(1):91-7
pubmed: 25104304
Cancer Res. 2015 Jan 1;75(1):194-202
pubmed: 25406193
Sci Rep. 2015 Jan 27;5:7979
pubmed: 25623281
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046
Neuro Oncol. 2016 Apr;18(4):507-17
pubmed: 26320116
Sci Transl Med. 2015 Sep 9;7(304):304ra143
pubmed: 26355032
Acta Neuropathol. 2016 Feb;131(2):309-319
pubmed: 26493382
Stem Cells Int. 2016;2016:7849890
pubmed: 26880988
Nat Commun. 2016 Feb 22;7:10743
pubmed: 26899176
Neuro Oncol. 2016 Sep;18(9):1219-29
pubmed: 26917237
Front Surg. 2016 Apr 15;3:21
pubmed: 27148537
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Curr Cancer Drug Targets. 2017;17(3):255-266
pubmed: 27528360
J Neurooncol. 2017 Jan;131(1):125-133
pubmed: 27644688
Sci Rep. 2016 Nov 23;6:37283
pubmed: 27876890
J Neurooncol. 2017 Apr;132(2):341-349
pubmed: 28074322
J Clin Invest. 2017 Feb 1;127(2):415-426
pubmed: 28145904
Mol Aspects Med. 2017 Jun;55:140-151
pubmed: 28223127
Neuro Oncol. 2017 Jul 1;19(7):887-896
pubmed: 28339582
Tumour Biol. 2017 Mar;39(3):1010428317692227
pubmed: 28347245
Ann Oncol. 2017 Jul 1;28(7):1448-1456
pubmed: 28407030
Front Oncol. 2017 Jun 16;7:120
pubmed: 28670569
Cancer Lett. 2017 Nov 1;408:174-181
pubmed: 28743531
Cell Mol Life Sci. 2018 Feb;75(3):385-402
pubmed: 28821904
Med Oncol. 2018 Jan 31;35(3):27
pubmed: 29387965
J Neurooncol. 2018 Oct;140(1):1-4
pubmed: 29998396
Stem Cells Transl Med. 2018 Oct;7(10):740-747
pubmed: 30133188
Cancer Cell. 2019 Jan 14;35(1):140-155.e7
pubmed: 30595505
Mol Cancer Res. 2019 May;17(5):1102-1114
pubmed: 30642878
JCI Insight. 2019 Jan 24;4(2):
pubmed: 30674721
Am J Pathol. 1971 Apr;63(1):37-56
pubmed: 4323476
Br J Neurosurg. 1996 Feb;10(1):103-7
pubmed: 8672252
Int J Cancer. 1996 Jul 17;67(2):275-82
pubmed: 8760599
Oncogene. 1997 May 1;14(17):2005-13
pubmed: 9160879
Virchows Arch. 1998 Nov;433(5):457-63
pubmed: 9849861